Bloom Lab Profile picture
May 21, 2022 19 tweets 10 min read Read on X
In this thread, I discuss what are candidates for the next mutational steps in evolution of #SARSCoV2 to evade neutralizing antibodies. TLDR: in addition to mutations at sites 452 & 486 in BA.4/5, watch for mutations at sites 346-348, 356, 444-446, & 468. (1/n)
As background, human CoVs evolve to erode antibody neutralization (). As result, typical person infected with common-cold CoV every few years, which “updates” their immunity to newer strains until a few more years of viral evolution erodes it again (2/n)
As most people know, this process is ongoing for #SARSCoV2, with new variants continuing to erode neutralization by antibodies elicited by old strains (like one in vaccine), which contributes to increasing re-infections & vaccine breakthroughs () (3/n)
Question I address here is which specific mutations are candidates for “next steps” in this antigenic evolution. I’ll focus only on spike’s receptor-binding domain (RBD), which is dominant but not exclusive target of neutralizing antibody response: (4/n)
To prospectively identify antibody escape mutations, @tylernstarr @AllieGreaney developed deep mutational scanning to map all mutations that reduce binding (science.org/doi/10.1126/sc…). Below is map of mutations that escape one monoclonal antibody (LY-CoV555 = bamlanivimab) (5/n)
Of course, human antibody response to infection & vaccination is polyclonal. To understand escape from that, we need to identify how mutations affect the spectrum of different neutralizing antibodies generated by human immune system (6/n)
As simple example, consider mix of 3 antibodies shown below. Full escape from mix requires combining mutations that escape each antibody. Note mutations can be redundant if they escape same antibody (484 & 490) or synergistic if escape different antibodies (484 & 417). (7/n)
We previously formalized this idea into an antibody escape calculator, which leverages deep mutational scanning for a large set of antibodies to estimate effects of mutations on polyclonal serum: academic.oup.com/ve/article/8/1… (8/n)
Originally calculator used data for few dozen antibodies generated by @tylernstarr @AllieGreaney in our group, but recently Sunney Xie, Richard Cao, @facyanOvO et al at @PKU1898 generated HUGE set of data for ~1,500 antibodies! (9/n)
Their data, which @facyanOvO generously posted on GitHub (github.com/jianfcpku/SARS…), now compose vast majority of info used by escape calculator. Such a large data set enables some pretty cool analyses. (10/n)
First, as has now been extensively described, antibodies elicited by early #SARSCoV2 (eg, current vaccine) that neutralize early strains (eg, Wuhan-Hu-1) strongly escaped by mutations at site 484 & also sites like 417, 346 & 446—all of which are mutated in some variants. (11/n)
Escape calculator also shows how Omicron BA.1 and BA.2 both have extensive escape from antibodies elicited by early #SARSCoV2, as is now well described. Importantly, it shows that 486 is site of largest escape from residual antibodies that still neutralize BA.1 / BA.2 (12/n)
In fact, using calculator we predicted back in Dec 2021 that site 486 was one to watch for future evolution (). And just last month, @tuliodna reported it was mutated in BA.4/BA.5, which have largest antibody escape of any variants yet described. (13/n)
So what might be virus’s next steps in antigenic evolution? We can subset on just antibodies elicited by early (pre-Omicron) strains that still neutralize BA.2. In addition to mutations already in BA.4/BA.5, sites of possible future escape include 346, 444-446 & 499. (14/n)
But importantly, sites of escape in BA.2 somewhat different for antibodies elicited by early strains FOLLOWED by BA.1 breakthrough. Comparing below image to that in prior Tweet you can see some different peaks, such as at 347-348, 356 & 468. (15/n)
This divergence in effects of mutations between people +/- prior BA.1 breakthrough is because exposure history shapes immunity. We will increasingly see variation in how #SARSCoV2 mutations impact antibodies of different people, as for influenza: elifesciences.org/articles/49324 (16/n)
Finally, antibody-escape calculator is available at jbloomlab.github.io/SARS2_RBD_Ab_e… You can select antibodies by exposure history (including past infection w SARS-CoV-1) & by what strains they neutralize, & click on sites to see impacts of mutations. (17/n)
Also, some slides going into more detail on the material in this thread are at slides.com/jbloom/escape-… (18/n)
And really embarrassingly, I mis-tagged @fucyanOvO who shared so much of the great data analyzed here. Sorry... 😞 (19/n)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Bloom Lab

Bloom Lab Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @jbloom_lab

Apr 20
In new study led by @bblarsen1 in collab w @veeslerlab @VUMC_Vaccines we map functional & antigenic landscape of Nipah virus receptor binding protein (RBP)


Results elucidate constraints on RBP function & provide insight re protein’s evolutionary potentialbiorxiv.org/content/10.110…
Nipah is bat virus that sporadically infects humans w high (~70%) fatality rate. Has been limited human transmission

Like other paramyxoviruses, Nipah uses two proteins to enter cells: RBP binds receptor & then triggers fusion (F) protein by process that is not fully understood
RBP forms tetramer in which 4 constituent monomers (which are all identical in sequence) adopt 3 distinct conformations

RBP binds to two receptors, EFNB2 & EFNB3

RBP’s affinity for EFNB2 is very high (~0.1 nM, over an order of magnitude higher than SARSCoV2’s affinity for ACE2) Image
Read 12 tweets
Mar 5
Over 4 yrs after being first to publicly release SARS-CoV-2 genome, Yong-Zhen Zhang just published large set of viral seqs from first stage of COVID-19 outbreak in China


He uses data to suggest scenarios re early outbreak & root of viral phylogenetic tree academic.oup.com/ve/advance-art…
Image
Zhang recruited nearly all COVID-19 patients hospitalized at Shanghai Public Health Center in first 2/3 (Jan-Sep) of 2020.

The largest source of Shanghai patients in Jan/Feb 2020 was imported cases from Wuhan or elsewhere in Hubei, thereby providing window into Wuhan outbreak. Image
Overall, Zhang obtained 343 near-full-length SARS-CoV-2 sequences from 226 distinct patients, including 133 sequences from samples collected no later than Feb-15-2020.

A phylogenetic tree showing these sequences is below. Image
Read 11 tweets
Feb 7
In new study led by Caleb Carr & @khdcrawford, we measure how all mutation to Lassa virus glycoprotein complex (GPC) affect cell entry & antibody escape

Results show how prospective assessment of effects of mutations can inform design of countermeasures
biorxiv.org/content/10.110…
As background, Lassa virus causes of thousands of deaths each year, mostly from spillovers from its rodent host, but there is occasional human-to-human transmission.

Lassa is biosafety-level-4 priority pathogen, & efforts are underway to develop vaccines & antibody therapeutics.
We used pseudovirus deep mutational scanning to study effects of nearly all 9,820 amino-acid mutations to Lassa’s GPC at biosafety-level-2 by making genotype-phenotype linked libraries of lentiviral pseudotypes
blog.addgene.org/viral-vectors-…
Image
Read 18 tweets
Jan 17
Here is my brief analysis of Dec-28-2019 SARSCoV2 submission to Genbank.

This analysis supports my conclusion to WSJ () that this submission does not tell origin of virus, but does show sequence known to Chinese Academy of Sciences weeks before released wsj.com/politics/natio…
Image
Here is link to my full analysis:

See also images of the same posted below (although it's probably just easier to click on link above and read HTML). github.com/jbloom/SARS2_2…



Image
Image
Image
Image
I also don't think Genbank/NCBI could have reasonably known at time that this sequence was so valuable given that Chinese govt did not announce they had sequence or had submitted it, and Genbank receives vast numbers of submissions.
Read 4 tweets
Dec 17, 2023
In new study led by Frances Welsh, we map how mutations to influenza affect neutralization by antibodies from humans of various ages

We find differences in mutation effects among age groups

Virus has evolved especially to escape antibodies of teenagers

biorxiv.org/content/10.110…
As background, human influenza constantly evolving. So people exposed to different strains, depending on their age & idiosyncratic history of infection/vaccination.

Different exposure histories cause people to make antibodies w different specificities

rupress.org/jem/article/21…
How does this person-to-person heterogeneity in antibody specificity affect influenza evolution?

That’s question we set out to answer

We used deep mutational scanning to measure how H3N2 HA mutations affect neutralization by serum antibodies from children, teenagers, and adults
Read 11 tweets
Nov 29, 2023
I wanted to highlight this pre-print by David Ho’s group on the neutralizing antibody response to new (XBB.1.5-based) COVID vaccine booster, as it illustrates some points related to paradigm of updating SARS-CoV-2 vaccines to keep pace w viral evolution.
biorxiv.org/content/10.110…
Recall original COVID vaccines worked very well against early SARS-CoV-2 strains

Unfortunately, virus has been evolving, so antibodies elicited by that vaccine don’t neutralize newer viral variants very well

(Other human CoVs also evolve same way: ) journals.plos.org/plospathogens/…
Image
So in fall 2022, new booster was made that mixed new (at time) BA.5 variant & original strain. Hope was to boost neutralization of new variants.

Unfortunately, only sort of worked. Titers did go up, but not a relatively greater increase for new variants. Image
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(